Vaxart, Inc. - Common Stock (VXRT)

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

In today's session, these stocks are experiencing unusual volume.

Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vaccines for COVID-19 and norovirus.

VXRT stock results show that Vaxart missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company's cash runway into 2026.

Vaxart (VXRT) shares surged 23% in premarket session after receiving a $453 million project award from BARDA to conduct a COVID-19 vaccine study.